PIK3CA and anemia: The differential response is unclear and probably due to a sum of multiple factors including genomic background (such as constitutive active PI3K/Akt pathway due to PTEN loss or PIK3CA activating mutations) and patient-specific features (for example, treatment with recombinant human eritropoyetin to manage treatment-induced anemia).